Leatrice Olson, DO
Internal Medicine · Des Moines, IANPI 1447268198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 531 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,937 and has fallen 64.9% since, to $681 in 2025. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 531 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Pfizer$979
- Johnson & Johnson$974
- AstraZeneca$923
- AbbVie$766
- Lilly USA, LLC$620
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,35396%
- Education$3074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 73 | $1,159 |
| Pfizer | 70 | $979 |
| Johnson & Johnson | 62 | $974 |
| AstraZeneca | 48 | $923 |
| AbbVie(2 entities) | 44 | $766 |
| Lilly USA, LLC | 42 | $620 |
| Novo Nordisk | 32 | $404 |
| Amgen | 23 | $379 |
| Actelion Pharmaceuticals US, Inc. | 6 | $290 |
| Bayer | 14 | $268 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $240 |
| Merck | 14 | $203 |
| Astellas Pharma US Inc | 9 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $192 |
| Sanofi-aventis U.S. LLC | 9 | $171 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $147 |
| Mylan Specialty L.p. | 9 | $132 |
| GSK | 8 | $126 |
| Abbott | 7 | $109 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Sunovion Pharmaceuticals Inc. | 9 | $86 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 1 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Novartis | 1 | $13 |
| Boston Scientific | 1 | $12 |
How this compares
$8,660 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $89,160 |
| JardianceEmpagliflozin | 69 | $63,779 |
| FarxigaDapagliflozin Propanediol | 33 | $34,217 |
| JanuviaSitagliptin Phosphate | 32 | $32,062 |
| TrulicityDulaglutide | 19 | $28,983 |
| XareltoRivaroxaban | 16 | $26,797 |
| EliquisApixaban | 31 | $22,628 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 50 | $14,608 |
| Victoza 3-PakLiraglutide | 11 | $13,396 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 310 | $13,388 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $12,643 |
| Spiriva RespimatTiotropium Bromide | 24 | $12,554 |
| MounjaroTirzepatide | 12 | $12,095 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $11,399 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $404 | $89,16074 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $1,159 | $76,33393 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $620 | $41,07831 claims |
| AstraZenecaFarxiga, Symbicort | $923 | $41,01159 claims |
| MerckJanuvia | $203 | $32,06232 claims |
| Johnson & JohnsonXarelto | $974 | $26,79716 claims |
| PfizerEliquis | $979 | $22,62831 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $126 | $15,44228 claims |
| NovartisEntresto | $13 | $8,12012 claims |
| AbbVieSynthroid | $766 | $1,50813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Des Moines
- Todd JensenDes Moines$9K
- Louise ConveryDes Moines$8K
- Laura KerseyDes Moines$8K
- Anthonia IjeliDes Moines$7K
- Omar JaradatDes Moines$4K
- Garrett WiltDes Moines$4K
- Kyle ClayDes Moines$3K
- Tyler MummDes Moines$2K
- Justin BergerDes Moines$2K
- Leah LaageideDes Moines$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.